Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers

Trial Profile

Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2014

At a glance

  • Drugs TCN 202 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Theraclone Sciences
  • Most Recent Events

    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 10 Sep 2013 Results were presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2013, according to a Theraclone Sciences media release.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed, according to a Theraclone Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top